SummaCor: Advancing Pulsatile Blood Flow Technology | MedTech World North America 2026

Why It Matters

By restoring physiologic pulsatile flow, Sumacore’s pump promises fewer complications and broader clinical adoption, unlocking a multi‑billion‑dollar market in circulatory support and organ perfusion.

Key Takeaways

• Sumacore's linear displacement pump delivers true pulsatile blood flow.
• Pulsatile flow reduces shear stress, lowering hemolysis and thrombosis risk.
• Device achieves 5 L/min at 200 rpm, outperforming Impella’s 2.5 L/min.
• Quick 90‑second insertion/removal enables use in primary care settings.
• Total addressable market spans $8‑11 B, with organ‑procurement potential $10 B by 2034.

Summary

Manish Wadwa, CEO of Sumacore, presented the company’s linear displacement pulsatile pump at MedTech World North America 2026, highlighting the clinical need for true pulsatile blood flow in mechanical circulatory support. He contrasted pulsatile physiology with the flat‑line output of current non‑pulsatile devices such as Impella, ECMO, and cardiopulmonary bypass machines, linking the lack of hemodynamic energy to complications like gut ischemia, endothelial dysfunction, and hyper‑adrenergic states.

The core technology features a self‑expanding mesh and a parachute‑like element that creates and retracts a pulse, delivering up to 5 L/min at 200 cycles per minute for the LCAP and 90 cycles per minute for ECMO applications. This low‑reciprocating rate generates markedly lower shear stress than high‑speed rotary pumps, reducing hemolysis, bleeding, and thrombosis. The device can be positioned and removed within 90 seconds, mirroring intra‑aortic balloon pump deployment.

Wadwa emphasized performance advantages: the LCAP’s flow exceeds the Impella’s 2.5 L/min while operating at a fraction of the rotational speed (200 rpm vs. 30‑40 k rpm). He cited 28 pre‑clinical studies, seven global patents, and readiness for a first‑in‑human trial. The addressable market includes high‑risk coronary stenosis and cardiogenic shock ($8‑11 B total), with an emerging $10 B organ‑procurement and perfusion segment projected by 2034.

If adopted, Sumacore’s technology could shift the standard of care toward physiologic pulsatility, improve multi‑organ outcomes, and open new revenue streams across tertiary and primary care facilities. Its rapid deployment and lower complication profile position it to capture significant market share in both existing and emerging circulatory support niches.

Original Description

Can restoring natural pulsatile blood flow improve outcomes for patients requiring mechanical circulatory support?

At MedTech World North America 2026, Dr. Manish Wadhwa, MD, FHRS, FACC, FESC, Chief Executive Officer of SummaCor, presented the company's innovative portfolio of pulsatile pumps designed to address the limitations of today's non-pulsatile circulatory support technologies.

In this company showcase, Dr. Wadhwa explains how SummaCor's proprietary linear displacement pump technology aims to deliver physiological blood flow while reducing complications associated with conventional devices.

Key topics include:

• The importance of pulsatile blood flow in human physiology

• Challenges associated with non-pulsatile mechanical circulatory support

• SummaCor's linear cardiac assist pulsatile pump (LCAP) technology

• Applications in cardiogenic shock, high-risk PCI, ECMO, and cardiopulmonary bypass

• Reducing risks related to bleeding, thrombosis, hemolysis, and organ dysfunction

• Preclinical validation and first-in-human study preparations

SummaCor is developing a new generation of mechanical circulatory support technologies designed to improve patient outcomes while expanding access to life-saving cardiac care.

Subscribe to our channel for the latest company showcases, startup pitches, panel discussions, and insights from the global MedTech ecosystem.

#MedTechWorld #MedTechWorldNorthAmerica2026 #SummaCor #CardiovascularInnovation #MechanicalCirculatorySupport #ECMO #Cardiology #MedicalDevices #HealthcareInnovation #MedTechStartup